Tweets
For daily recaps, content and updates from #ACR24 head to https://t.co/eL0bMhnFiu @RheumNow with input from colleagues in the faculty
@synovialjoints
@bella_mehta
@ericdeinmd
@AkhilSoodMD.
@DrMiniDey
@CaoilfhionnMD
@ebrhuem
@rheumarampa
@Dr_Brian_MD
@AdelaCastro222
@JihaRheum… https://t.co/a3FQjGokhn https://t.co/1g3Fi01HWG
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
3 months 3 weeks ago
#Ianalumab
300 mg sc q monthly
B cell depleted and changes BAFF signalling
👇⬇️IFN
May be promising in #lupus #SLE
+data in primary #Sjogrens
ACR24 @RheumNow @ACRheum
Abst#2425
Needs Phase3
➡️I suspect safer than CAR T and Bispecific T cell engagers but
? ⬇️efficacy
Janet Pope @Janetbirdope ( View Tweet )
3 months 3 weeks ago
ACR24 take homes
➡️#Inflammatory #myositis
#Upadacitinib improved MDA5 ILD
#Baricitinib 4mg/d good in myositis delayed start #RCT
#Tofacitinb ➡️help for skin, calcinosis, rash in case series
➡️RCT ongoing
JAKi is ‘jacked’ in muscles 💪🏿
#ACR24 @RheumNow @ACRheum
1731 0348
Janet Pope @Janetbirdope ( View Tweet )
3 months 3 weeks ago
Biggest absence award at #ACR24 @ACRheum @RheumNow
🥇
Absence of discussion on
👇
#Oral #Surveillance
Except for maybe
Monitoring for mouth ulcers and cancers
issues are not resolved but we are comfortable with ambiguity!
Janet Pope @Janetbirdope ( View Tweet )
3 months 3 weeks ago
Taking CAR-T for a Test Drive
What is CAR-T? How can you get a healthy dose of it at #ACR24? And what does it mean for the future? Read on to find out!
https://t.co/TnNHzWQndp https://t.co/qWgwjiEdLF
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Are Emulation Trials a Fantasy?
Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
https://t.co/x6NogGQksW https://t.co/f8o8N55tlJ
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
axSpA: Moving the needle in time to diagnosis
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes.… https://t.co/wnwtj8jj0q https://t.co/Pds2uxVfJV
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Assessment and management of axSpA
Dr. Antoni Chan reports on abstract 0818, Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration, and abstract 0819, The Assessment of SpondyloArthritis International Society… https://t.co/ropQJdElyb https://t.co/IVn5u2l7iP
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Hypoxia seems to exacerbate neutrophil activation by ANCA
- enhanced F-Actin polymerization
- enhanced NET formation
Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns?
@RheumNow #ACR24 https://t.co/KxaeMvkd2t
Links:
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
3 months 3 weeks ago
Prior studies have shown that IFN is increased in non-lesional skin of SLE pts.
In this study, they found a ⬆️ expression of IFN stimulated genes (ISGs) in pts w/ a history of CLE.
No correlation w/ CLASI act & IFN scores but only few pts.
@RheumNow #ACR24 abs2678 https://t.co/cPT6yPkoCb
Links:
sheila @RHEUMarampa ( View Tweet )
3 months 3 weeks ago